Know Cancer

or
forgot password

Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients


N/A
18 Years
N/A
Open (Enrolling)
Female
Estrogen Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer

Thank you

Trial Information

Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients


PRIMARY OBJECTIVES:

I. Investigate the status of ERalpha-p53 interaction in ERalpha-positive, p53-wild type
breast tumors in untreated patients and examine how tamoxifen (tamoxifen citrate) therapy
modifies this interaction.

II. To confirm the wild type status of p53 and analyze the functional status of p53 pathway
by monitoring expression of selected p53-target genes in tumors in patients who have or have
not been treated with tamoxifen.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive standard of care surgical therapy. Patients may undergo standard
surgery.

Arm II: Patients receive tamoxifen citrate orally (PO) daily for 4 weeks in the absence of
disease progression or unacceptable toxicity. Patients may then undergo standard surgery.


Inclusion Criteria:



- The patient must consent to be in the study and must have signed an approved consent
form conforming to institutional guidelines

- Core biopsy should definitively demonstrate invasive carcinoma

- Invasive carcinoma should be ERalpha receptor positive

- The tumor should be approximately at least 1 cm, to account for variability in
imaging and imaging occult disease (physical exam, mammography, ultrasound); we
recognize that from time to time because of this variation, there might not be enough
tissue available for analysis after surgical excision but this will allow the
greatest opportunity to capture as many eligible patients as possible

- Patients in whom surgical excision of the tumor is part of standard of care
management

- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1

- Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at
screening for patients of child-bearing potential (this is routinely done if the
patient is premenopausal and having surgery)

- Consent to participate in Data Bank and BioRepository (DBBR)

Exclusion Criteria:

- Male patients are not eligible for this study

- Female patients with inoperable tumors or women with stage 4 disease diagnosed on
computed tomography (CT), positron emission tomography (PET), PET/CT or bone scan

- Patients with diagnosis by fine needle aspiration (FNA) cytology only

- Pregnant or lactating women

- Prior therapy for breast cancer, including irradiation, chemo-, immuno- and/or
hormonal therapy

- Patients receiving any hormonal therapy, e.g.,ovarian hormonal replacement therapy,
infertility medications etc., are not eligible

- Nonmalignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
preclude the patient from being subjected to surgical excision

- Psychiatric or addictive disorders that would preclude obtaining informed consent

- Patients known or suspected to have hypercoagulable syndrome or with history of
venous or arterial thrombosis, stroke, transient ischemic attack (TIA), or pulmonary
embolism

- Women with non-invasive disease or microinvasion are not eligible

- Women undergoing neoadjuvant chemotherapy are not eligible

- Women currently on tamoxifen for prevention are not eligible

- Patients shall not receive any herbal/alternative therapies such as flaxseed or soy
products or black cohosh

- Patients with a known mutation in p53 (Li Fraumer/ Syndrome)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Comparisons of ERalpha-p53 interaction (positive or negative) between independent treatment and control groups

Outcome Description:

The proportions of patients with positive ChIP assay will be compared with Fisher's Exact Test. Descriptive statistics such as frequencies and relative frequencies will be computed for all categorical variables. Numeric variables will be summarized using simple descriptive statistics such as mean, standard deviation, quartiles, etc. Ninety-five percent confidence intervals will be computed when appropriate.

Outcome Time Frame:

4 weeks

Safety Issue:

No

Principal Investigator

Stephen Edge

Investigator Role:

Principal Investigator

Investigator Affiliation:

Roswell Park Cancer Institute

Authority:

United States: Federal Government

Study ID:

I 110907

NCT ID:

NCT01658566

Start Date:

December 2007

Completion Date:

Related Keywords:

  • Estrogen Receptor-positive Breast Cancer
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Stage IV Breast Cancer
  • Breast Neoplasms

Name

Location
Roswell Park Cancer Institute Buffalo, New York  14263
University of Chicago Chicago, Illinois  60637